Tanya Keenan1, Beverly Moy1, Edmund A Mroz1, Kenneth Ross1, Andrzej Niemierko1, James W Rocco1, Steven Isakoff1, Leif W Ellisen1, Aditya Bardia2. 1. Tanya Keenan, Beverly Moy, Kenneth Ross, Andrzej Niemierko, Steven Isakoff, Leif W. Ellisen, and Aditya Bardia, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Edmund A. Mroz and James W. Rocco, Ohio State University/Wexner Medical Center and James Cancer Center, Ohio State University, Columbus, OH. 2. Tanya Keenan, Beverly Moy, Kenneth Ross, Andrzej Niemierko, Steven Isakoff, Leif W. Ellisen, and Aditya Bardia, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Edmund A. Mroz and James W. Rocco, Ohio State University/Wexner Medical Center and James Cancer Center, Ohio State University, Columbus, OH. bardia.aditya@mgh.harvard.edu.
Abstract
PURPOSE: African American women are more likely to die as a result of breast cancer than white women. The influence of somatic genomic profiles on this racial disparity is unclear. We aimed to compare the racial distribution of tumor genomic characteristics and breast cancer recurrence. METHODS: We assessed white and African American women with stage I to III breast cancer diagnosed from 1988 to 2013 and primary tumors submitted to The Cancer Genome Atlas from 2010 to 2014. We used Cox proportional hazards models to evaluate the association of race and genetic traits with tumor recurrence. RESULTS: We investigated exome sequencing and gene expression data in 663 and 711 white and 105 and 159 African American women, respectively. African Americans had more TP53 mutations (42.9% v 27.6%; P = .003) and fewer PIK3CA mutations (20.0% v 33.9%; P = .008). Intratumor genetic heterogeneity was greater in African American than white tumors overall by 5.1 units (95% CI, 2.4 to 7.7) and within triple-negative tumors by 4.1 units (95% CI, 1.4 to 6.8). African Americans had more basal tumors by the 50-gene set predictor using the predication analysis of microarray method (PAM50; 39.0% v 18.6%; P < .001) and fewer PAM50 luminal A tumors (17.0% v 34.7%; P < .001). Among triple-negative subtypes, African Americans had more basal-like 1 and mesenchymal stem-like tumors. African Americans had a higher risk of tumor recurrence than whites (hazard ratio, 2.22; 95% CI, 1.05 to 4.67). Racial differences in TP53 mutation, PAM50 basal subtype, and triple-negative tumor prevalence but not intratumor genetic heterogeneity influenced the magnitude and significance of the racial disparity in tumor recurrence. CONCLUSION: African Americans had greater intratumor genetic heterogeneity and more basal gene expression tumors, even within triple-negative breast cancer. This pattern suggests more aggressive tumor biology in African Americans than whites, which could contribute to racial disparity in breast cancer outcome.
PURPOSE: African American women are more likely to die as a result of breast cancer than white women. The influence of somatic genomic profiles on this racial disparity is unclear. We aimed to compare the racial distribution of tumor genomic characteristics and breast cancer recurrence. METHODS: We assessed white and African American women with stage I to III breast cancer diagnosed from 1988 to 2013 and primary tumors submitted to The Cancer Genome Atlas from 2010 to 2014. We used Cox proportional hazards models to evaluate the association of race and genetic traits with tumor recurrence. RESULTS: We investigated exome sequencing and gene expression data in 663 and 711 white and 105 and 159 African American women, respectively. African Americans had more TP53 mutations (42.9% v 27.6%; P = .003) and fewer PIK3CA mutations (20.0% v 33.9%; P = .008). Intratumor genetic heterogeneity was greater in African American than white tumors overall by 5.1 units (95% CI, 2.4 to 7.7) and within triple-negative tumors by 4.1 units (95% CI, 1.4 to 6.8). African Americans had more basal tumors by the 50-gene set predictor using the predication analysis of microarray method (PAM50; 39.0% v 18.6%; P < .001) and fewer PAM50 luminal A tumors (17.0% v 34.7%; P < .001). Among triple-negative subtypes, African Americans had more basal-like 1 and mesenchymal stem-like tumors. African Americans had a higher risk of tumor recurrence than whites (hazard ratio, 2.22; 95% CI, 1.05 to 4.67). Racial differences in TP53 mutation, PAM50 basal subtype, and triple-negative tumor prevalence but not intratumor genetic heterogeneity influenced the magnitude and significance of the racial disparity in tumor recurrence. CONCLUSION: African Americans had greater intratumor genetic heterogeneity and more basal gene expression tumors, even within triple-negative breast cancer. This pattern suggests more aggressive tumor biology in African Americans than whites, which could contribute to racial disparity in breast cancer outcome.
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Nataliya G Batina; Amy Trentham-Dietz; Ronald E Gangnon; Brian L Sprague; Marjorie A Rosenberg; Natasha K Stout; Dennis G Fryback; Oguzhan Alagoz Journal: Breast Cancer Res Treat Date: 2013-02-16 Impact factor: 4.872
Authors: Lori A Field; Brad Love; Brenda Deyarmin; Jeffrey A Hooke; Craig D Shriver; Rachel E Ellsworth Journal: Cancer Date: 2011-07-28 Impact factor: 6.860
Authors: Vanessa B Sheppard; Claudine Isaacs; George Luta; Shawna C Willey; Marc Boisvert; Felicity W K Harper; Karen Smith; Sara Horton; Minetta C Liu; Yvonne Jennings; Fikru Hirpa; Felicia Snead; Jeanne S Mandelblatt Journal: Breast Cancer Res Treat Date: 2013-04-16 Impact factor: 4.872
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Tomi F Akinyemiju; Amr S Soliman; Glenn Copeland; Mousumi Banerjee; Kendra Schwartz; Sofia D Merajver Journal: PLoS One Date: 2013-04-29 Impact factor: 3.240
Authors: S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera Journal: Clin Exp Metastasis Date: 2018-05-23 Impact factor: 5.150
Authors: Tess O'Meara; Anton Safonov; David Casadevall; Tao Qing; Andrea Silber; Brigid Killelea; Christos Hatzis; Lajos Pusztai Journal: Breast Cancer Res Treat Date: 2019-02-06 Impact factor: 4.872
Authors: Meijing Wu; Jason Miska; Ting Xiao; Peng Zhang; J Robert Kane; Irina V Balyasnikova; James P Chandler; Craig M Horbinski; Maciej S Lesniak Journal: J Neurooncol Date: 2019-01-31 Impact factor: 4.130
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872